Browse studies

Find your next paid study

7 recruiting studies matching your filters

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Orally Administered NNZ-2591 Compared With Placebo in Pediatric Participants With Phelan-McDermid Syndrome

This Phase 3, randomized, double-blind, parallel-group (2-arm), placebo-controlled, multicenter study will evaluate the efficacy and safety of NNZ-2591 compare…

Phelan-McDermid Syndrome

Estimated

~$10 – $8,750

Neuren Pharmaceuticals LimitedNCT07281079

Phase 3

A Phase 3 Open-label Extension Study to Investigate the Long-term Safety and Efficacy of Orally Administered NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

This Phase 3, open-label extension, multicenter study will evaluate long-term safety, tolerability and efficacy of NNZ-2591 in pediatric participants with Phel…

Phelan-McDermid Syndrome

Estimated

~$10 – $8,750

Neuren Pharmaceuticals LimitedNCT07593391

Phase 1

A Phase 1/2, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, and Clinical Activity Study of a Single Dose of JAG201 Gene Therapy Delivered Via Intracerebroventricular Administration in Participants With SHANK3 Haploinsufficiency

This is a Phase 1/2, first in human, open-label, dose-escalation study to evaluate the safety, tolerability, and clinical activity of a single dose of JAG201 a…

SHANK3 HaploinsufficiencyPhelan-McDermid Syndrome

Estimated

~$10 – $8,750

Jaguar Gene Therapy, LLCNCT06662188

Phase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)

A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.

pMNIgANNephrotic Syndrome+2 more

Estimated

~$10 – $8,750

Vera Therapeutics, Inc.NCT06983028

Nephrotic Syndrome Study Network Under the Rare Diseases Clinical Research Network

Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financia…

Minimal Change Disease (MCD)Membranous NephropathyGlomerulosclerosis, Focal Segmental

Estimated

~$10 – $750

University of MichiganNCT01209000

Observational

Implementing Precision Medicine for Glomerular Diseases in the Nephrotic Syndrome Study Network (NEPTUNE)

NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial match…

Nephrotic Syndrome in ChildrenFocal Segmental GlomerulosclerosisMinimal Change Disease+6 more

Estimated

~$10 – $6,250

University of MichiganNCT04571658

Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis (FSGS) and Minimal Change Disease (MCD)

The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include conte…

Focal Segmental GlomerulosclerosisMinimal Change DiseaseFSGS+1 more

Estimated

~$10 – $750

University of MichiganNCT05650619